Lessons from maraviroc clinical trials

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Maraviroc is the first commercially available HIV chemokine receptor antagonist targeting HIV that utilizes the CCR5 chemokine receptor (R5 tropic). The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) trials were two randomized, placebo-controlled studies designed to demonstrate the activity of maraviroc in triple-class-experienced HIV individuals, with a primary end point of viral load suppression at 48 weeks. Maraviroc outperformed the placebo plus optimized background (OBT) arm, and exhibited a favorable safety profile with low discontinuation rates, which equaled those of the placebo plus OBT group. The results of these trials led to maraviroc receiving regulatory approval for the treatment of HIV.

Original languageEnglish (US)
Pages (from-to)649-651
Number of pages3
JournalExpert Review of Anti-Infective Therapy
Issue number6
StatePublished - Jun 2011


  • CCR5 antagonist
  • maraviroc
  • R5-tropic HIV
  • randomized controlled trial
  • triple-class failure

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology
  • Virology


Dive into the research topics of 'Lessons from maraviroc clinical trials'. Together they form a unique fingerprint.

Cite this